These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25583363)

  • 1. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.
    Furman CA; Roof RA; Moritz AE; Miller BN; Doyle TB; Free RB; Banala AK; Paul NM; Kumar V; Sibley CD; Newman AH; Sibley DR
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1448-61. PubMed ID: 25583363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D
    Kumar V; Moritz AE; Keck TM; Bonifazi A; Ellenberger MP; Sibley CD; Free RB; Shi L; Lane JR; Sibley DR; Newman AH
    J Med Chem; 2017 Feb; 60(4):1478-1494. PubMed ID: 28186762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors.
    Michino M; Donthamsetti P; Beuming T; Banala A; Duan L; Roux T; Han Y; Trinquet E; Newman AH; Javitch JA; Shi L
    Mol Pharmacol; 2013 Dec; 84(6):854-64. PubMed ID: 24061855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors.
    Lane JR; Chubukov P; Liu W; Canals M; Cherezov V; Abagyan R; Stevens RC; Katritch V
    Mol Pharmacol; 2013 Dec; 84(6):794-807. PubMed ID: 24021214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.
    Rangel-Barajas C; Malik M; Taylor M; Neve KA; Mach RH; Luedtke RR
    J Neurochem; 2014 Nov; 131(4):418-31. PubMed ID: 25041389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
    Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR
    J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of N-phenyl homopiperazine analogs as potential dopamine D3 receptor selective ligands.
    Li A; Mishra Y; Malik M; Wang Q; Li S; Taylor M; Reichert DE; Luedtke RR; Mach RH
    Bioorg Med Chem; 2013 Jun; 21(11):2988-98. PubMed ID: 23618707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and preliminary bioactivity evaluation of bitopic benzopyranomorpholine analogues as selective dopamine D3 receptor ligands as anti-drug addiction therapeutic agents.
    Cai J; Huang M; Wang Y; Chen X; Ji M
    Bioorg Med Chem Lett; 2021 Sep; 48():128269. PubMed ID: 34284107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists.
    Xu W; Wang X; Tocker AM; Huang P; Reith ME; Liu-Chen LY; Smith AB; Kortagere S
    ACS Chem Neurosci; 2017 Mar; 8(3):486-500. PubMed ID: 27801563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the D
    Moritz AE; Bonifazi A; Guerrero AM; Kumar V; Free RB; Lane JR; Verma RK; Shi L; Newman AH; Sibley DR
    ACS Chem Neurosci; 2020 Oct; 11(20):3309-3320. PubMed ID: 32969645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examining the Effects of Sodium Ions on the Binding of Antagonists to Dopamine D2 and D3 Receptors.
    Newton CL; Wood MD; Strange PG
    PLoS One; 2016; 11(7):e0158808. PubMed ID: 27379794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctive binding properties of the negative allosteric modulator, [
    Fasciani I; Pietrantoni I; Rossi M; Mannoury la Cour C; Aloisi G; Marampon F; Scarselli M; Millan MJ; Maggio R
    Eur J Pharmacol; 2018 Jan; 819():181-189. PubMed ID: 29223348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Substituted
    Lee B; Taylor M; Griffin SA; McInnis T; Sumien N; Mach RH; Luedtke RR
    Molecules; 2021 May; 26(11):. PubMed ID: 34073405
    [No Abstract]   [Full Text] [Related]  

  • 16. Using click chemistry toward novel 1,2,3-triazole-linked dopamine D3 receptor ligands.
    Keck TM; Banala AK; Slack RD; Burzynski C; Bonifazi A; Okunola-Bakare OM; Moore M; Deschamps JR; Rais R; Slusher BS; Newman AH
    Bioorg Med Chem; 2015 Jul; 23(14):4000-12. PubMed ID: 25650314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors.
    Silvano E; Millan MJ; Mannoury la Cour C; Han Y; Duan L; Griffin SA; Luedtke RR; Aloisi G; Rossi M; Zazzeroni F; Javitch JA; Maggio R
    Mol Pharmacol; 2010 Nov; 78(5):925-34. PubMed ID: 20702763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
    Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
    J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of C9 alkoxy analogues of (-)-stepholidine as dopamine receptor ligands.
    Madapa S; Gadhiya S; Kurtzman T; Alberts IL; Ramsey S; Reith M; Harding WW
    Eur J Med Chem; 2017 Jan; 125():255-268. PubMed ID: 27688181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D
    Whiting RL; Choppin A; Luehr G; Jasper JR
    J Pharmacol Exp Ther; 2021 Oct; 379(1):85-95. PubMed ID: 34253646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.